Decoding the ATT Landscape: Mechanisms, Evidence, and the Evolving Role of Pharmacy

Faculty

James “Trey” Bateman, MD, MPH
Moderator
Associate Professor of Neurology
VCU Department of Neurology
Richmond, VA
Shigeki Hirano, MD, PhD
Virtual Guest Commentator
Clinical Associate Professor
Department of Neurology, Graduate School of Medicine
Chiba University
Dementia Medical/Care Center, Chiba University Hospital
Chiba, Japan
Frank Jessen, MD
Professor
Department of Psychiatry
University of Cologne
Germany
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP
Virtual Guest Commentator
Dean and Professor
Pacific University School of Pharmacy
Hillsboro, OR

Statement of Need

Alzheimer’s disease (AD) affects more than 55 million individuals worldwide, leading to progressive decline in memory, cognition, and ability to perform activities of daily living (ADLs). Recent advancements in amyloid-targeting therapies (ATTs) have created new opportunities to alter disease progression in patients with early symptomatic AD. However, many clinicians lack familiarity with the latest diagnostic criteria, biomarker use, and patient selection considerations necessary to determine the appropriateness of these treatments. There is a clear need for education to support evidence-based decision-making regarding the identification and management of patients who may benefit from ATTs.

In this first installment of a CMEO Snack Series on treating AD, expert faculty will help learners identify the appropriateness of ATTs for patients with early symptomatic AD.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify the appropriateness of ATTs for patients with early symptomatic AD

Financial Support

Supported by an educational grant from Lilly.

Target Audience

Clinical pharmacists practicing in the United States and Europe (excluding United Kingdom).

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-25-128-H01-P).

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Bateman reports no financial relationships to disclose.

Dr. Hirano reports the following financial relationships:

Research Support: Nihon Medi-Physics, Co., Ltd.

Speakers Bureau: Eli Lilly Japan and Daiichi Sankyo Company, Limited

Dr. Jessen reports the following financial relationships:

Advisory Board: Abbvie Inc.; AC Immune SA; Eisai Co., Ltd.; Grifols, S.A.; Lilly; Novo Nordisk A/S; Priavoid GmbH; Roche; and Sanofi

Grants: Roche

Speakers Bureau: Eisai Co., Ltd.; GE HealthCare; Janssen-Cilag; Lilly; and Novo Nordisk A/S

Dr. Marvanova reports no financial relationships to disclose.

Caregiver Planner

Donna Gabriel, PhD reports no financial relationships to disclose.

 

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Joshua Caballero, PharmD, BCPP, FCCP (Peer Reviewer)
Evan Luberger (Planning Committee)
Estelle Perera (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-299-033125-11

Decoding the ATT Landscape: Mechanisms, Evidence, and the Evolving Role of Pharmacy
Event Date: 03/31/2026